News PepGen Inc.

Equities

PEPG

US7133171055

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
14.2 ^USD	-2.00%		+19.03%	+108.82%

Mar. 13	PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	MT
Mar. 13	PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PepGen to Participate in Upcoming Investor Conferences	Mar. 13	GL
PepGen to Participate in Upcoming Investor Conferences	Mar. 13	AQ
PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	Mar. 13	MT
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	Mar. 13	DJ
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 13	GL
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 13	AQ
Wedbush Trims PepGen's PT to $20 From $21, Incorporates Offering, Adjusts Share Count Assumptions; Maintains Outperform Rating	Mar. 07	MT
Transcript : PepGen Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	Mar. 06	GL
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	Mar. 06	AQ
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 04	GL
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 04	AQ
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 04	CI
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	Feb. 20	MT
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	Feb. 20	GL
PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	Feb. 20	CI
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock	Feb. 07	GL
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	Jan. 17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PepGen Inc.

Equities

PEPG

US7133171055

Summary

Filters